Stryker Co. (SYK) Shares Sold by Sumitomo Mitsui Trust Holdings Inc.
Sumitomo Mitsui Trust Holdings Inc. trimmed its holdings in Stryker Co. (NYSE:SYK) by 0.1% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,339,774 shares of the medical technology company’s stock after selling 1,603 shares during the period. Sumitomo Mitsui Trust Holdings Inc.’s holdings in Stryker were worth $264,632,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other large investors have also bought and sold shares of the business. BKD Wealth Advisors LLC boosted its stake in shares of Stryker by 2.0% during the 4th quarter. BKD Wealth Advisors LLC now owns 3,646 shares of the medical technology company’s stock valued at $572,000 after buying an additional 72 shares during the last quarter. Virtu Financial LLC purchased a new position in shares of Stryker during the 4th quarter valued at approximately $215,000. Landsberg Bennett & Dubbaneh LLC purchased a new position in shares of Stryker during the 4th quarter valued at approximately $1,926,000. Horan Securities Inc. purchased a new position in shares of Stryker during the 4th quarter valued at approximately $30,000. Finally, Hendley & Co. Inc. boosted its stake in shares of Stryker by 11.9% during the 4th quarter. Hendley & Co. Inc. now owns 7,550 shares of the medical technology company’s stock valued at $1,183,000 after buying an additional 802 shares during the last quarter. 74.71% of the stock is owned by hedge funds and other institutional investors.
Several research firms recently issued reports on SYK. Zacks Investment Research lowered Stryker from a “buy” rating to a “hold” rating in a research report on Tuesday, May 14th. Canaccord Genuity upped their price target on Stryker from $190.00 to $195.00 and gave the company a “buy” rating in a research report on Wednesday, April 24th. Deutsche Bank upped their price target on Stryker from $181.00 to $208.00 and gave the company a “buy” rating in a research report on Wednesday, April 24th. Oppenheimer upped their price target on Stryker from $183.00 to $192.00 and gave the company an “outperform” rating in a research report on Wednesday, April 24th. Finally, Wells Fargo & Co upped their price target on Stryker from $214.00 to $219.00 and gave the company an “outperform” rating in a research report on Monday, April 1st. Six analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company’s stock. Stryker has a consensus rating of “Buy” and an average target price of $196.85.
Stryker (NYSE:SYK) last issued its earnings results on Tuesday, April 23rd. The medical technology company reported $1.88 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.84 by $0.04. Stryker had a return on equity of 26.72% and a net margin of 25.38%. The firm had revenue of $3.52 billion for the quarter, compared to analyst estimates of $3.51 billion. During the same period last year, the company earned $1.68 earnings per share. The firm’s revenue for the quarter was up 8.5% on a year-over-year basis. Equities research analysts expect that Stryker Co. will post 8.15 earnings per share for the current fiscal year.
The business also recently announced a quarterly dividend, which will be paid on Wednesday, July 31st. Shareholders of record on Friday, June 28th will be given a $0.52 dividend. This represents a $2.08 annualized dividend and a yield of 1.12%. The ex-dividend date of this dividend is Thursday, June 27th. Stryker’s dividend payout ratio is presently 28.45%.
In other news, VP Katherine Ann Owen sold 29,247 shares of the firm’s stock in a transaction on Friday, March 8th. The stock was sold at an average price of $185.62, for a total transaction of $5,428,828.14. Following the transaction, the vice president now directly owns 11,131 shares of the company’s stock, valued at $2,066,136.22. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Glenn S. Boehnlein sold 2,700 shares of the firm’s stock in a transaction on Wednesday, May 8th. The shares were sold at an average price of $188.21, for a total value of $508,167.00. Following the transaction, the chief financial officer now directly owns 23,333 shares in the company, valued at $4,391,503.93. The disclosure for this sale can be found here. Insiders sold 111,550 shares of company stock worth $21,376,317 over the last ninety days. 7.20% of the stock is owned by corporate insiders.
COPYRIGHT VIOLATION WARNING: “Stryker Co. (SYK) Shares Sold by Sumitomo Mitsui Trust Holdings Inc.” was originally reported by Watch List News and is the sole property of of Watch List News. If you are accessing this piece on another publication, it was copied illegally and republished in violation of U.S. & international trademark & copyright legislation. The original version of this piece can be read at https://www.watchlistnews.com/stryker-co-syk-shares-sold-by-sumitomo-mitsui-trust-holdings-inc/3017862.html.
Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical devices for use in various medical specialties.
Featured Article: Asset Allocation and Your Retirement
Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Co. (NYSE:SYK).
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.